IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

(2011) Niklas Thon et al.   CANCER

Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

(2011) C. Hartmann et al.   CLINICAL CANCER RESEARCH

Molecular Classification of Low-Grade Diffuse Gliomas

(2010) Young-Ho Kim et al.   AMERICAN JOURNAL OF PATHOLOGY

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

(2010) Floris H. Groenendijk et al.   JOURNAL OF NEURO-ONCOLOGY

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

(2010) Nanne K Kloosterhof et al.   LANCET ONCOLOGY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Low-grade gliomas in older patients

(2009) David A. Schomas et al.   CANCER

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Operative techniques for gliomas and the value of extent of resection

(2009) Nader Sanai et al.   Neurotherapeutics

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE